Grant: Canada Postdoctoral Research Award (CPRA) program
Direct Payment
$140,000.00
Atovaquone as a Tumor Microenvironment Modulator in Ovarian Cancer: Insights from a Microfluidic Tumor Model
FY 2025-26
Summary
Ovarian cancer is one of the most deadly cancers affecting women, with high-grade serous carcinoma being the most common type. Unfortunately, this cancer is often resistant to standard treatments like chemotherapy, which limits patient survival. New therapies are urgently needed. One of the biggest challenges is that ovarian tumors create a protective environment that prevents immune cells from entering and fighting the cancer. Special cells called cancer-associated fibroblasts (CAFs) play a major role in this process by helping tumors grow, building a dense tissue structure around them, and blocking immune attack.
Our research explores whether an existing medicine, called atovaquone, could be repurposed as a new ovarian cancer therapy. Atovaquone is an oral drug already approved for malaria, which makes it safe, affordable, and widely available. Early studies from our group have shown that it can slow down cancer cell growth and reduce tumor cell migration. Even more promising, we found that atovaquone may also weaken the signals that tumors use to "activate" fibroblasts and stiffen the tissue around them. By doing so, it could reduce barriers that keep immune cells out.
To study this, we are using an advanced "tumor-on-a-chip" system. This microfluidic model allows us to grow miniature 3D tumors together with fibroblasts and immune cells in a controlled setting. We will test how CAFs promote tumor growth and how atovaquone affects cancer behavior, fibroblast activity, tissue remodeling, and immune cell entry.
If successful, this research could show that an affordable, already-approved drug can be repurposed to make ovarian cancer more vulnerable to both the immune system and other treatments. In the long term, this approach may also help identify which patients are most likely to benefit, moving us closer to more personalized and effective cancer therapies.
Department
Program
Canada Postdoctoral Research Award (CPRA) program
Recipient
Location
Wisconsin, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
537551
Name
Bérubé Michael
Region
Wisconsin
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Atovaquone as a Tumor Microenvironment Modulator in Ovarian Cancer: Insights from a Microfluidic Tumor Model
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Atovaquone; Cancer-Associated Fibroblasts; Collagen Remodeling; Microfluidics; Ovarian Cancer; Oxphos Inhibition; Tumor Microenvironment
Abstract
Ovarian cancer is one of the most deadly cancers affecting women, with high-grade serous carcinoma being the most common type. Unfortunately, this cancer is often resistant to standard treatments like chemotherapy, which limits patient survival. New therapies are urgently needed. One of the biggest challenges is that ovarian tumors create a protective environment that prevents immune cells from entering and fighting the cancer. Special cells called cancer-associated fibroblasts (CAFs) play a major role in this process by helping tumors grow, building a dense tissue structure around them, and blocking immune attack.
Our research explores whether an existing medicine, called atovaquone, could be repurposed as a new ovarian cancer therapy. Atovaquone is an oral drug already approved for malaria, which makes it safe, affordable, and widely available. Early studies from our group have shown that it can slow down cancer cell growth and reduce tumor cell migration. Even more promising, we found that atovaquone may also weaken the signals that tumors use to "activate" fibroblasts and stiffen the tissue around them. By doing so, it could reduce barriers that keep immune cells out.
To study this, we are using an advanced "tumor-on-a-chip" system. This microfluidic model allows us to grow miniature 3D tumors together with fibroblasts and immune cells in a controlled setting. We will test how CAFs promote tumor growth and how atovaquone affects cancer behavior, fibroblast activity, tissue remodeling, and immune cell entry.
If successful, this research could show that an affordable, already-approved drug can be repurposed to make ovarian cancer more vulnerable to both the immune system and other treatments. In the long term, this approach may also help identify which patients are most likely to benefit, moving us closer to more personalized and effective cancer therapies.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Bérubé, Michael
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~